Live chat
Biogen

Associate Director, Global SMA Marketing

Biogen - Cambridge, MA

The Associate Director will be a key member of the global launch for the treatment of spinal muscular atrophy (SMA), a rare pediatric neuromuscular disease. They will have an extraordinary opportunity in a therapeutic area with high unmet need, translating market insights into actionable activities to make treatment available to all appropriate patients.

This individual will be part of a small but highly functioning team of commercial professionals who are tasked with delivering during the launch period while also focusing on the future. They will have shared accountability for global revenue, market share, and budget targets. They will report to the Senior Director, Global Commercial Lead for SMA.

Primary areas of responsibility include:

• Ensure launch readiness worldwide, through in-depth collaboration with affiliates, regions, and value chain functions, with a notable focus on new geographies

• Lead the advertising agency in the evolution of unbranded marketing deliverables, including messaging and creative concept. The work will likely include design and execution of market research as well thought leader or community engagement

• Lead cross-functional deep dives into key strategic issues for the product, such as segmentation and customer experience, in order to guide global planning and affiliate execution

• Drive day-to-day performance oversight through the execution and interpretation of dashboards and enabling in-depth discussion within global marketing, regions, and affiliates

• Participate as a key member of the named patient program working team. Activities include on-boarding of a new vendor and operations lead

• Cultivate and maintain strong relationships with global medical and value & access, regional and affiliate marketers worldwide, and other key members of the asset team

Requisition Number

32982BR

Employment Category

Full-Time Regular

External Posting Title

Associate Director, Global SMA Marketing

Job Category

Sales & Marketing

Qualifications

The successful candidate will be an experienced individual with a strong track record of commercial and marketing success in the pharmaceutical or biopharmaceutical industry. They will be a proven brand manager with strong strategic thinking, market analysis, and marketing execution skills.

They will be a self-starter who can thrive in a fast-paced and challenging environment, who is able to effectively balance multiple priorities and is always willing to pitch in to help the team achieve results. They will be a skilled collaborator, able to drive decision-making and accountability in a cross-functional environment through strong influence and leadership skills. They will possess solid communication skills, including the ability to interface across geographies and functions within Biogen as well as with customers.

Importantly, the successful candidate will put patients first and have a significant respect for science.

Experience Required:

• 8 years of commercial and marketing experience in the pharmaceutical or biotechnology industry

• Affiliate brand marketing experience highly preferred but not required

• Rare disease or orphan drug/device/diagnostic experience preferred but not required

• Launch experience preferred but not required

Anticipated travel: 20-30% international

Education

Bachelor\u0027s Degree Required

Advanced Degree Preferred

Experience Level

Mid-Senior Level

Summary

The Associate Director will be a key member of the global launch for the treatment of spinal muscular atrophy (SMA), a rare pediatric neuromuscular disease. They will have an extraordinary opportunity in a therapeutic area with high unmet need, translating market insights into actionable activities to make treatment available to all appropriate patients.

Action

7 days 18 hours ago

Biogen

apply

Associate Director, Global SMA Marketing Biogen - Cambridge, MA, United States

   

Location: Cambridge, MA

Company Profile:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.